Visacor

País: Nova Zelândia

Língua: inglês

Origem: Medsafe (Medicines Safety Authority)

Ingredientes ativos:

Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin;  ;  ;  

Disponível em:

AstraZeneca Limited

DCI (Denominação Comum Internacional):

Rosuvastatin calcium 5.2 mg (= 5 mg rosuvastatin)

Dosagem:

5 mg

Forma farmacêutica:

Film coated tablet

Composição:

Active: Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin       Excipient: Calcium phosphate Crospovidone Hypromellose as Opadry Yellow Iron oxide yellow as Opadry Yellow Lactose monohydrate as Opadry Yellow   Magnesium stearate Microcrystalline cellulose Titanium dioxide as Opadry Yellow Triacetin as Opadry Yellow

Unidades em pacote:

Blister pack, Al/Al foil, 7 tablets

Classe:

Prescription

Tipo de prescrição:

Prescription

Fabricado por:

Lonza AG

Indicações terapêuticas:

VISACOR is indicated to: - Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDLcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). - Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia). Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (eg. LDL apheresis) or alone if such treatments are unavailable.

Resumo do produto:

Package - Contents - Shelf Life: Blister pack, Al/Al foil - 7 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, Al/Al foil - 30 tablets - 36 months from date of manufacture stored at or below 30°C

Data de autorização:

2009-07-31